REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon(®)) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma

BACKGROUND: REFLECT is the first prospective study of Sandoz biosimilar rituximab (SDZ-RTX) in patients with diffuse large B-cell lymphoma (DLBCL). OBJECTIVE: To evaluate the 2-year effectiveness and safety of SDZ-RTX as first-line treatment for DLBCL. DESIGN: Real-world, multicenter, open-label, si...

Descripción completa

Detalles Bibliográficos
Autores principales: Welslau, Manfred, Kubuschok, Boris, Topaly, Julian, Otremba, Burkhard, Wolff, Thomas, Bryn, Galyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363888/
https://www.ncbi.nlm.nih.gov/pubmed/37492394
http://dx.doi.org/10.1177/20406207231183765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363888/
https://www.ncbi.nlm.nih.gov/pubmed/37492394
http://dx.doi.org/10.1177/20406207231183765

Ejemplares similares